<DOC>
	<DOC>NCT00126412</DOC>
	<brief_summary>The study is designed to study the effectiveness of 123I-mIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroblastoma or phaeochromocytoma.</brief_summary>
	<brief_title>Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Subject must either have: 1. known or suspected neuroblastoma OR 2. known or suspected phaeochromocytoma Subjects are not eligible for the study if they have any clinically active, serious, lifethreatening disease other than neuroblastoma or phaeochromocytoma with a life expectancy of less than 30 days or where participation in the study might compromise the management of the subject or other reason that in the judgement of the investigator(s) makes the subject unsuitable for participation in the study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Phaeochromocytoma</keyword>
	<keyword>Neuroblastoma</keyword>
	<keyword>diagnosis</keyword>
	<keyword>123I-mIBG</keyword>
</DOC>